BioMarin Pharmaceutical
Market Cap
US$13.5b
Last Updated
2020/10/30 04:00 UTC
Data Sources
Company Financials +
Executive Summary
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. More Details
Rewards
Risk Analysis
Snowflake Analysis
Slightly overvalued with limited growth.
Similar Companies
Share Price & News
How has BioMarin Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMRN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-4.0%
BMRN
-2.5%
US Biotechs
-4.1%
US Market
1 Year Return
1.1%
BMRN
25.0%
US Biotechs
12.0%
US Market
Return vs Industry: BMRN underperformed the US Biotechs industry which returned 25% over the past year.
Return vs Market: BMRN underperformed the US Market which returned 12% over the past year.
Shareholder returns
| BMRN | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.0% | -2.5% | -4.1% |
| 30 Day | -2.2% | -2.1% | -0.2% |
| 90 Day | -37.9% | -1.8% | 2.8% |
| 1 Year | 1.1%1.1% | 27.1%25.0% | 14.6%12.0% |
| 3 Year | -11.5%-11.5% | 18.0%12.0% | 35.8%26.8% |
| 5 Year | -35.2%-35.2% | 8.9%1.0% | 75.2%55.6% |
Price Volatility Vs. Market
How volatile is BioMarin Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is There An Opportunity With BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) 28% Undervaluation?1 month ago | Simply Wall St
Declining Stock and Decent Financials: Is The Market Wrong About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)?1 month ago | Simply Wall St
We Wouldn't Rely On BioMarin Pharmaceutical's (NASDAQ:BMRN) Statutory Earnings As A GuideValuation
Is BioMarin Pharmaceutical undervalued compared to its fair value and its price relative to the market?
31.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMRN ($74.42) is trading below our estimate of fair value ($109.11)
Significantly Below Fair Value: BMRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMRN is poor value based on its PE Ratio (109.5x) compared to the US Biotechs industry average (27.5x).
PE vs Market: BMRN is poor value based on its PE Ratio (109.5x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: BMRN is poor value based on its PEG Ratio (6.7x)
Price to Book Ratio
PB vs Industry: BMRN is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (3.3x).
Next Steps
Future Growth
How is BioMarin Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
16.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMRN's forecast earnings growth (16.3% per year) is above the savings rate (2.2%).
Earnings vs Market: BMRN's earnings (16.3% per year) are forecast to grow slower than the US market (22% per year).
High Growth Earnings: BMRN's earnings are forecast to grow, but not significantly.
Revenue vs Market: BMRN's revenue (18.1% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: BMRN's revenue (18.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMRN's Return on Equity is forecast to be low in 3 years time (14.3%).
Next Steps
Past Performance
How has BioMarin Pharmaceutical performed over the past 5 years?
42.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMRN has a large one-off gain of $69.4M impacting its June 30 2020 financial results.
Growing Profit Margin: BMRN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BMRN has become profitable over the past 5 years, growing earnings by 42.2% per year.
Accelerating Growth: BMRN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BMRN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).
Return on Equity
High ROE: BMRN's Return on Equity (3.8%) is considered low.
Next Steps
Financial Health
How is BioMarin Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: BMRN's short term assets ($2.6B) exceed its short term liabilities ($813.3M).
Long Term Liabilities: BMRN's short term assets ($2.6B) exceed its long term liabilities ($1.3B).
Debt to Equity History and Analysis
Debt Level: BMRN's debt to equity ratio (44.6%) is considered high.
Reducing Debt: BMRN's debt to equity ratio has increased from 28.1% to 44.6% over the past 5 years.
Debt Coverage: BMRN's debt is not well covered by operating cash flow (9.7%).
Interest Coverage: Insufficient data to determine if BMRN's interest payments on its debt are well covered by EBIT.
Balance Sheet
Next Steps
Dividend
What is BioMarin Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BMRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.9yrs
Average management tenure
CEO
Jean-Jacques Bienaimé (67 yo)
15.42yrs
Tenure
US$18,405,856
Compensation
Mr. Jean-Jacques Bienaimé, MBA, serves as a Member of Strategic Advisory Board at Longwood Fund. He has been the Chief Executive Officer of Biomarin Pharmaceutical Inc. since June 2005. He served as Direct ...
CEO Compensation Analysis
Compensation vs Market: Jean-Jacques's total compensation ($USD18.41M) is above average for companies of similar size in the US market ($USD11.21M).
Compensation vs Earnings: Jean-Jacques's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 15.42yrs | US$18.41m | 0.30% $ 40.7m | |
| Executive VP & Chief Commercial Officer | 8yrs | US$6.34m | 0.034% $ 4.6m | |
| President of Worldwide Research & Development | 4yrs | US$7.02m | 0.057% $ 7.7m | |
| Executive VP & CFO | 0.75yr | no data | 0.016% $ 2.2m | |
| Group VP & Chief Accounting Officer | 0.33yr | no data | 0.00075% $ 101.2k | |
| CTO and Executive VP of Global Manufacturing & Technical Operations | 0.42yr | no data | no data | |
| Chief Scientific Strategy Officer | no data | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 16.75yrs | US$2.71m | 0.036% $ 4.9m | |
| Senior VP & Chief Compliance Officer | no data | no data | no data | |
| Group Vice President of Corporate & Business Development | no data | no data | no data | |
| Senior Vice President of Human Resources | 1.75yrs | no data | no data |
2.9yrs
Average Tenure
53.5yo
Average Age
Experienced Management: BMRN's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 15.42yrs | US$18.41m | 0.30% $ 40.7m | |
| Lead Independent Director | 5.33yrs | US$510.52k | 0.042% $ 5.6m | |
| Independent Director | 14.83yrs | US$465.52k | 0.021% $ 2.9m | |
| Independent Director | 4.75yrs | US$454.90k | 0.015% $ 2.0m | |
| Independent Director | 18.25yrs | US$477.02k | 0.035% $ 4.7m | |
| Independent Director | 13.33yrs | US$458.27k | 0.0080% $ 1.1m | |
| Independent Director | 4.25yrs | US$454.27k | 0.0050% $ 669.4k | |
| Independent Director | 6.58yrs | US$454.27k | 0.0078% $ 1.1m | |
| Independent Director | 3.08yrs | US$471.90k | 0.0041% $ 556.0k | |
| Independent Director | 1.25yrs | US$412.50k | no data |
5.3yrs
Average Tenure
67yo
Average Age
Experienced Board: BMRN's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BMRN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
BioMarin Pharmaceutical Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: BioMarin Pharmaceutical Inc.
- Ticker: BMRN
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$13.496b
- Shares outstanding: 181.35m
- Website: https://www.biomarin.com
Number of Employees
Location
- BioMarin Pharmaceutical Inc.
- 770 Lindaro Street
- San Rafael
- California
- 94901
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BMRN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jul 1999 |
| BM8 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 1999 |
| BMRN | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jul 1999 |
| 0HNC | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jul 1999 |
| BM8 | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Jul 1999 |
| BMRN * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jul 1999 |
| B1MR34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 2 REPR 1 COM | BR | BRL | Jan 2020 |
Biography
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products inclu ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/30 04:00 |
| End of Day Share Price | 2020/10/29 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.